Related Experiment Videos
[High-dose melphalan in patients with multiple myeloma]
P Moreau1, M Le Bonniec, J L Harousseau
1Service d'hématologie clinique, CHU Hôtel-Dieu, place Alexis-Ricordeau, 44093 Nantes.
Bulletin Du Cancer
|April 22, 1999
Summary
High-dose melphalan, with or without stem cell support, is a leading treatment for multiple myeloma. This review summarizes its clinical use and explores future research directions for this potent therapy.
Area of Science:
- Hematology
- Oncology
- Clinical Pharmacology
Context:
- Multiple myeloma treatment landscape since 1983.
- Increasing use of high-dose melphalan in clinical trials.
- Autologous stem cell support as a common adjunct therapy.
Purpose:
- To review and synthesize clinical data on intravenous high-dose melphalan for multiple myeloma.
- To examine the efficacy and safety of high-dose melphalan therapy.
- To identify promising avenues for future research in melphalan-based treatments.
Summary:
- High-dose melphalan, often combined with autologous stem cell support, has emerged as a primary treatment option for newly diagnosed multiple myeloma patients.
- Clinical evidence supports its role as a treatment of choice, demonstrating significant efficacy.
- This report consolidates existing knowledge and highlights areas for further investigation.
Impact:
- Provides a comprehensive overview of high-dose melphalan in multiple myeloma management.
- Informs clinical decision-making for newly diagnosed patients.
- Guides future research efforts to optimize melphalan-based therapeutic strategies.